Back to Journals » Therapeutics and Clinical Risk Management » Volume 17

Emerging B-Cell Therapies in Systemic Lupus Erythematosus

Authors Bag-Ozbek A, Hui-Yuen JS

Received 9 October 2020

Accepted for publication 29 December 2020

Published 14 January 2021 Volume 2021:17 Pages 39—54

DOI https://doi.org/10.2147/TCRM.S252592

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh


Ayse Bag-Ozbek,1 Joyce S Hui-Yuen2– 4

1Division of Rheumatology, Renaissance School of Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA; 2Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, New Hyde Park, NY, USA; 3Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 4Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institute for Medical Research, Manhasset, NY, USA

Correspondence: Joyce S Hui-Yuen
Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, 1991 Marcus Avenue, Suite M100, New Hyde Park, NY 11040, USA
Tel +1 516.472.3700
Fax +1 516.472.3752
Email jhuiyuen@nshs.edu

Abstract: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE. This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab, obinutuzumab, obexelimab, epratuzumab, daratumumab), B-cell survival factors (belimumab, tabalumab, atacicept, blisibimod), or B-cell intracellular functions (ibrutinib, fenebrutinib, proteasome inhibitors), for the management of SLE. It focuses on ongoing clinical trials and real-world post-marketing use, where available, including their safety profiles, and concludes with our recommendations for B-cell-centric approaches to the management of SLE.

Keywords: systemic lupus erythematosus, treatment, novel B-cell therapies, belimumab, rituximab, epratuzumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]